Chronic pancreatitis
Conditions
Interventions
One group receives PRFLSN after a positive trial block with bupivacaine, the
other group receives no extra treatment besides optimal medical treatment.
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with chronic pancreatitis presenting with significant abdominal pain of pancreatic origin. Pain will be considered significant if there is at least 1 episode of pain every month requiring analgesics during the preceding 3 months, or at least 1 episode of severe pain requiring hospitalization in the preceding 3 months. *Pancreatic pain (NRS-score >5 out of 10), resistant to medical therapy (including opiods), with a duration of at least three months
Exclusion criteria
Exclusion criteria: Patients with pseudocysts, bile duct obstruction, duodenal obstruction or pancreatic cancer. Age younger than 18 years A noncooperative patient Coagulopathy Previous splanchnic nerve denervation Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of reduction of pain after PRFLSN for a period of at least 6 months and preferably one year. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Level of pain reduction after PRFLSN compared to optimal medical treatment * Reduction in the number of painful days per month * Reduction of medication use (NSAID*s and opioids) (MQS) * Quality of life (QLC-30, PAN-28 (chronic pancreatitis specific questionnaire), EQ-5D, BDI) * Reduction in number of man-lost days per month * Weight gain | — |
Countries
Netherlands
Outcome results
None listed